FlashRNA provides a proprietary RNA delivery platform that merges lentiviral cell transfer efficiency with bacteriophage RNA packaging, enabling high‑performance multi‑RNA delivery both in vitro and in vivo. The technology supports applications such as gene therapy, genome editing, cell reprogramming, vaccination, and immunotherapy, offering low immunogenicity and the capacity to deliver up to four large RNA constructs (up to 10 kb) for advanced therapeutic development.
Funding
Funding not disclosed
Founders
Product
Problem
Developing RNA‑based therapeutics requires efficient delivery of multiple large RNA molecules while avoiding immune activation and genomic integration, challenges that limit the potency and safety of gene therapy, genome editing, cell reprogramming, vaccines, and immunotherapies.
Solution
FlashRNA offers a proprietary RNA delivery platform that fuses the high cell‑transfer efficiency of lentiviral vectors with the RNA‑packaging capability of bacteriophage particles. The resulting RNA‑competent vector can transport up to four RNA cargos of up to 10 kb each, enabling simultaneous expression of multiple proteins in a single administration. Because the RNAs are of biological origin and encapsulated in a natural human cell membrane, the platform exhibits low immunogenicity and does not integrate into the host genome, eliminating reverse‑transcription and integrase activity. In preclinical studies, the vaccine formulation demonstrated a 500‑fold increase in potency over conventional lipid nanoparticles at equivalent RNA doses. The technology is positioned for applications in gene therapy, transient CRISPR‑Cas9 delivery, iPSC reprogramming, high‑efficacy vaccination, and multi‑component immunotherapy.
Target Audience
Primary customers are biotech and pharmaceutical companies developing RNA‑based therapeutics, including gene‑therapy developers, CRISPR‑based genome editors, cell‑reprogramming platforms, vaccine manufacturers, and immunotherapy programs.
Features
- Hybrid particle combining lentiviral cell entry with bacteriophage RNA packaging for high transduction efficiency
- Capacity to deliver up to four distinct RNA species, each up to 10 kb in length
- Natural human cell‑membrane envelope providing low immunogenicity and biocompatibility
- No genomic integration: absence of reverse transcription and integrase activity for enhanced safety
- Proven 500‑fold potency increase versus lipid nanoparticles in Covid‑19 vaccine models
- Suitable for both in‑vitro and in‑vivo applications across gene therapy, genome editing, cell reprogramming, vaccination, and immunotherapy